Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia-Reference-Cited by-同舟云学术

Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia

Published:2015-10-16 Issue:5 Volume:171 Page:763-775
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Awasthi Aradhana¹,Ayello Janet¹,Van de Ven Carmella¹,Elmacken Mona¹,Sabulski Anthony¹,Barth Matthew J.²,Czuczman Myron S.²,Islam Humayun³,Klein Christian⁴,Cairo Mitchell S.¹³⁵⁶⁷

Affiliation:

1. Department of Pediatrics; New York Medical College; Valhalla NY USA

2. Department of Medicine; Roswell Park Cancer Institute; Buffalo NY USA

3. Department of Pathology; New York Medical College; Valhalla NY USA

4. Roche Pharmaceutical Research & Early Development; Roche Innovation Centre; Zurich Switzerland

5. Department of Medicine; New York Medical College; Valhalla NY USA

6. Department of Microbiology & Immunology; New York Medical College; Valhalla NY USA

7. Department of Cell Biology & Anatomy; New York Medical College; Valhalla NY USA

Funder

Pediatric Cancer Research Foundation

Children Cancer Fund

St. Baldrick's foundation

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13764/fullpdf

Reference44 articles.

1. The future role of monoclonal antibody therapy in childhood acute leukaemias;Barth;British Journal of Haematology,2012a

2. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma;Barth;British Journal of Haematology,2012b

3. Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report;Barth;British Journal of Haematology,2013

4. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection;Beers;Blood,2010

5. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab;Bologna;The Journal of Immunology,2011

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Refractory Burkitt Lymphoma: Diagnosis and Interventional Strategies;Blood and Lymphatic Cancer: Targets and Therapy;2024-03

2. New monoclonal antibodies for the treatment of acute lymphoblastic leukemia;Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal;2024

3. A phase 2 and pharmacological study of sapanisertib in patients with relapsed and/or refractory acute lymphoblastic leukemia;Cancer Medicine;2023-11-13

4. FCRL1 immunoregulation in B cell development and malignancy;Frontiers in Immunology;2023-09-25

5. Multi-targeted immunotherapeutics to treat B cell malignancies;Journal of Controlled Release;2023-06